NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









United Immunity, Co., Ltd.

United Immunity, Co., Ltd.

Private
TokyoHealthcare & Life Scienceshttps://unitedimmunity.co.jp/

Last Round

Grant

Feb 27, 2026

Total Funding Raised

$71.37M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

United Immunity, Co., Ltd. is a biotechnology company that develops nanotechnology-based immunotherapy for the treatment of cancer and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

myeloid cell targetingclinical-stage biotechdrug delivery platformimmunotherapysolid tumor therapymacrophage targetingLNP deliveryin-vivo CAR-MCAR-M therapynanoparticle drug deliverytumor microenvironmentpullulan-based nanoparticlescold tumorTAM targetingTLR agonistbiotech licensingmRNA delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

United Immunity, Co., Ltd. Comparables

Compare United Immunity, Co., Ltd. with similar companies based on industry and business-model similarity.

United Immunity, Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

United Immunity, Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 27, 2026
DebtMar 15, 2024
VC RoundSep 11, 2023
Series BSep 7, 2021
Series A ExtensionMar 31, 2021
Series A
Jun 7, 2019

Key People

Founding team and executive leadership

Naozumi Harada

Scientific Founder and Chief Technology Officer

Founding Team

United Immunity, Co., Ltd. Investors

Notable investors and investment history

United Immunity, Co., Ltd. investors
InvestorRounds
Japan Agency for Medical Research and DevelopmentGrant
Mitsubishi UFJ CapitalSeries A
Axil CapitalSeries A
Aozora Corporate InvestmentDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 27, 2026

    $65M grant received from Japan Agency for Medical Research and Development.

  • Feb 21, 2025

    Grew 56% QoQ, from 9 to 14 employees.

United Immunity, Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

United Immunity, Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about United Immunity, Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTokyo
Employee Range17
Year Founded2017
Last FundingFeb 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.